**Supplementary Table 1. Antimicrobial Stewardship Program Resourcing and Impact on Broad Spectrum Antibiotic Use (Using Denominator of All Broad Spectrum Antibiotic Use)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Antibiotic Category | All (n=63)  Median % (IQR) | Funding or Resources (n=48)   Median %(IQR) | No Funding or Resources (n=15)  Median % (IQR) | Association between funding status and broad spectrum use  Unadjusted OR (95% CI) | Association between funding status and broad spectrum use  Adjusted OR (95% CI) |
| Fluoroquinolones | 16.6 (13.2 to 27.1) | 15.0 (12.8  to 23.7) | 24.6 (21.8 to 27.6) | 0.65 (0.41 to 1.03) | 0.64 (0.44 to 0.93) |
| Third generation cephalosporins | 30.3 (24.4 to 39.4) | 30.5 (24.3 to 40.8) | 30.1 (28.4 to 34.6) | 0.92 (0.59 to 1.46) | 1.05 (0.74  to 1.53) |
| Beta-lactam/beta-lactamase inhibitors | 27.4 (22.9 to 33.0) | 25.5 (23.0 to 31.9) | 29.2 (23.0 to 34.1) | 0.95 (0.75 to 1.20) | 0.94 (0.74 to 1.20) |
| Carbapenems | 7.6 (4.8 to 10.9) | 8.1 (5.3 to 11.8) | 6.0 (4.3 to 7.3) | 1.29 (0.93 to 1.80) | 1.11 (0.82 to 1.52) |
| Clindamycin | 1.3 (0.8 to 1.8) | 1.2 (0.6 to 1.6) | 2.1 (1.6 to 2.4) | 0.50 (0.34 to 0.74) | 0.55 (0.38 to 0.81) |
| Vancomycin | 10.5 (6.8 to 13.4) | 9.7 (6.7 to 13.6) | 11.1 (10.4 to 12.6) | 1.00 (0.61 to 1.65) | 0.89 (0.56 to 1.42) |
| Anti-Pseudomonal agents | 43.2 (36.1 to 49.8) | 41.3 (35.5 to 48.4) | 46.3 (42.9 to 52.4) | 0.77 (0.57 to 1.05) | 0.67 (0.54 to 0.88) |